Related Experiment Video
Updated: Jul 2, 2025
MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
Published on: December 13, 2017
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3
Mohamad Mohty1, Nizar J Bahlis2, Ajay K Nooka3
1Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRS 938, Paris, France.
Abstract:
The physical and emotional burden of relapsed or refractory multiple myeloma (RRMM) has been strongly correlated with declining health-related quality of life (QOL) in the patients it affects. This analysis evaluated patient-reported outcomes (PROs) from B-cell maturation antigen (BCMA)-naive (n = 123) and -exposed (n = 64) patients with RRMM enrolled in the MagnetisMM-3 study (NCT04649359) and treated with the humanized, bispecific BCMA-CD3 antibody elranatamab. Patients received two step-up doses of elranatamab (12 mg on day 1, 32 mg on day 4) before starting the full dose of 76 mg on day 8 (each cycle = 28 days). Global health status, functioning and symptom data were collected electronically using validated and myeloma-specific questionnaires. Improvements in PROs occurred early, with marked reductions in pain and disease symptoms and notable improvements in patients' outlook for their future health. Additionally, 40.2% of BCMA-naive and 52.6% of BCMA-exposed patients perceived their disease as 'a little better' or 'much better' by Cycle 1, Day 15. The results from this analysis demonstrated that elranatamab maintained or improved symptomology and general health status, regardless of prior BCMA-directed therapy. Thus, in addition to its clinical benefits, elranatamab therapy may sustain or improve QOL in heavily pretreated patients with RRMM.
Insights
Elranatamab treatment improved quality of life (QOL) for patients with relapsed or refractory multiple myeloma (RRMM). Patient-reported outcomes showed early symptom reduction and better outlook, regardless of prior B-cell maturation antigen (BCMA) therapy.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Relapsed or refractory multiple myeloma (RRMM) significantly impacts patients' health-related quality of life (QOL).
- Patient-reported outcomes (PROs) are crucial for assessing treatment efficacy in RRMM.
Purpose of the Study:
- To evaluate the impact of elranatamab on PROs in patients with RRMM.
- To assess QOL changes in BCMA-naive and BCMA-exposed RRMM patients treated with elranatamab.
Main Methods:
- Analysis of PRO data from the MagnetisMM-3 study (NCT04649359).
- Patients received escalating doses of elranatamab, a bispecific BCMA-CD3 antibody.
- Validated myeloma-specific questionnaires collected data on global health status, functioning, and symptoms.
Main Results:
- Improvements in PROs, including reduced pain and symptoms, were observed early in treatment.
- 40.2% of BCMA-naive and 52.6% of BCMA-exposed patients reported improvement by Cycle 1, Day 15.
- Elranatamab maintained or improved symptomology and general health status irrespective of prior BCMA-directed therapy.
Conclusions:
- Elranatamab therapy demonstrates potential to sustain or improve QOL in heavily pretreated RRMM patients.
- Beyond clinical benefits, elranatamab positively impacts patient-reported outcomes and overall well-being.
